Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1365.

https://doi.org/10.1182/blood-2019-131420

Published: 2019

Journal Articles

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

Paola Minetto, MD, Debora Soncini, PhD, Fabio Guolo, MD, Samantha Ruberti, BSc, PhD, Veronica Retali, Paola Contini, Nadia Bisso, MD, Nikki Di Felice, MD, Giulia Rivoli, MD, Antonia Cagnetta, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD, Michele Cea, MD

Blood (2018) 132 (Supplement 1): 3221.

https://doi.org/10.1182/blood-2018-99-119622

Published: 2018

Journal Articles

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Fabio Guolo, MD, Paola Minetto, MD, Annalisa Kunkl, MD, Elisabetta Tedone, Marino Clavio, MD, Maurizio Miglino, PhD, Fabrizio Caviglia, Nicoletta Colombo, PhD, Antonia Cagnetta, MD, Michele Cea, MD, Filippo Ballerini, MD, Jean Louis Ravetti, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2018-99-118984

Published: 2018

Journal Articles

Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib

Blood (2017) 130 (Supplement 1): 2884.

https://doi.org/10.1182/blood.V130.Suppl_1.2884.2884

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

Paola Minetto, MD, Debora Soncini, PhD, Antonia Cagnetta, MD, Fabio Guolo, MD, Veronica Retali, Giulia Rivoli, MD, Nadia Bisso, MD, Nikki Di Felice, MD, Maurizio Miglino, PhD, Letizia Canepa, MD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Michele Cea

Blood (2017) 130 (Supplement 1): 1796.

https://doi.org/10.1182/blood.V130.Suppl_1.1796.1796

Published: 2017

Journal Articles

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Micaela Bergamaschi, MD, Giulia Rivoli, MD, Letizia Canepa, MD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5671.

https://doi.org/10.1182/blood.V128.22.5671.5671

Published: 2016

Journal Articles

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Davide Lovera, MD, Fabio Guolo, MD, Nicoletta Colombo, PhD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5222.

https://doi.org/10.1182/blood.V128.22.5222.5222

Published: 2016

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

Journal Articles

A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment

Yu-Tzu Tai, PhD, Chirag Acharya, MD, Gang An, MD PhD, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Hua Jiang, MDPhD, Hans van Eenennaam, PhD, Andrea van Elsas, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2014) 124 (21): 2098.

https://doi.org/10.1182/blood.V124.21.2098.2098

Published: 2014

Journal Articles

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

Mariateresa Fulciniti, PhD, Rajya Lakshmi Bandi, BS, Nicola Amodio, PhD, Antonia Cagnetta, MD, William Senapedis, PhD, Erkan Baloglu, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3381.

https://doi.org/10.1182/blood.V124.21.3381.3381

Published: 2014

Journal Articles

NFκB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival

Chirag Acharya, MD, Gang An, MD PhD, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Hua Jiang, MDPhD, Yu-Tzu Tai, PhD, Kenneth C. Anderson, MD

Blood (2014) 124 (21): 3384.

https://doi.org/10.1182/blood.V124.21.3384.3384

Published: 2014

Journal Articles

Functional and Molecular Impact Of Dp1-Dependent Alternate Splicing In Multiple Myeloma

Mariateresa Fulciniti, PhD, Manoj Bashin, Ph.D, Mehmet Kemal Samur, PhD, Rajya Bandi, Parantu K Shah, PhD, Antonia Cagnetta, MD, Cheng Li, PhD, Florence Magrangeas, PhD, Stephane Minvielle, PhD, Herve Avet-Loiseau, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 1845.

https://doi.org/10.1182/blood.V122.21.1845.1845

Published: 2013

Journal Articles

Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor

Teresa Calimeri, MD, Mehmet Kemal Samur, PhD, Nicola Amodio, PhD, Michele Cea, MD, Antonia Cagnetta, MD, Mariateresa Fulciniti, PhD, Sophia Adamia, PhD, Marco Rossi, MD, Yu-Tzu Tai, PhD, Fortunato Morabito, MD, Abdel Kareem Azab, BPharm, PhD, Stephane Minvielle, PhD, Herve Avet-Loiseau, MD, Cheng Li, PhD, Jean-Bernard Lazaro, PhD, Kenneth C. Anderson, Masood A. Shammas, Pierfrancesco Tassone, MD, Nikhil C. Munshi, MD

Blood (2013) 122 (21): 124.

https://doi.org/10.1182/blood.V122.21.124.124

Published: 2013

Journal Articles

Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing

Yu-Tzu Tai, PhD, Chirag Acharya, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Patrick A Mayes, PhD, Jenny L Craigen, PhD, Louise Gliddon, James Smothers, Amanda L Christie, B.S., Andrew L. Kung, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 877.

https://doi.org/10.1182/blood.V122.21.877.877

Published: 2013

Journal Articles

Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NFκB Signaling

Yu-Tzu Tai, PhD, Chirag Acharya, MD, Mike Y Zhong, Michele Cea, MD, Antonia Cagnetta, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 681.

https://doi.org/10.1182/blood.V122.21.681.681

Published: 2013

Journal Articles

Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications

Antonia Cagnetta, MD, Michele Cea, MD, Sophia Adamia, PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Marco Gobbi, MD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3121.

https://doi.org/10.1182/blood.V122.21.3121.3121

Published: 2013

Journal Articles

Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells

Michele Cea, MD, Antonia Cagnetta, MD, Mariateresa Fulciniti, PhD, Yu-Tzu Tai, PhD, Chirag Acharya, Mike Zhong, Teru Hideshima, MD, PhD, Marco Gobbi, MD, Nikhil Munshi, MD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 276.

https://doi.org/10.1182/blood.V122.21.276.276

Published: 2013

Journal Articles

Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.

Blood (2012) 120 (21): 2932.

https://doi.org/10.1182/blood.V120.21.2932.2932

Published: 2012

Journal Articles

Intracellular NAD + Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity

Antonia Cagnetta, MD, Michele Cea, MD, Chirag Acharya, MD, Teresa Calimeri, MD, Yu-Tzu Tai, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Franco Patrone, Marco Gobbi, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 330.

https://doi.org/10.1182/blood.V120.21.330.330

Published: 2012

NARROW

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors

CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD+ Depleting Agents

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment

Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs)

NFκB Signaling and Mcl-1 Are Critical in B Cell Maturation Antigen-Promoted Multiple Myeloma Cell Growth and Survival

Functional and Molecular Impact Of Dp1-Dependent Alternate Splicing In Multiple Myeloma

Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor

Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing

Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NFκB Signaling

Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications

Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells

Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.

Intracellular NAD + Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only